135124-70-8

Basic information

• Product Name: 3-(Aminomethyl)-5-bromopyridine 97%
• Synonyms: 3-(Aminomethyl)-5-bromopyridine 97%;(5-BROMO-3-PYRIDINYL)METHYLAMINE;5-BROMO-3-PYRIDINEMETHANAMINE;5-BROMO-3-PYRIDINEMETHYLAMINE;3-(Aminomethyl)-5-bromopyridine;3-(Aminomethyl)-5-bromopyridine 95+%;(5-Bromopyridin-3-yl)methylamine;(5-Bromopyridin-3-yl)methylamine, alpha-Amino-5-bromo-3-picoline
• CAS NO: 135124-70-8
• Molecular Formula: C₆H₇BrN₂
• Molecular Weight: 187.05
• Product Categories: Building Blocks;Pyridine
• Mol File: 135124-70-8.mol

Chemical Properties

• Boiling Point: 269.4°Cat760mmHg
• Flash Point: 116.7°C
• Appearance: /
• Density: 1.574g/cm³
• Vapor Pressure: 0.00726mmHg at 25°C
• Refractive Index: 1.596
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 7.75±0.29(Predicted)
• CAS DataBase Reference: 3-(Aminomethyl)-5-bromopyridine 97%(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(Aminomethyl)-5-bromopyridine 97%(135124-70-8)
• EPA Substance Registry System: 3-(Aminomethyl)-5-bromopyridine 97%(135124-70-8)

Safety Data

• Hazard Codes: C
• Hazardous Substances Data: 135124-70-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-(Aminomethyl)-5-bromopyridine 97% is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of biologically active compounds. Its presence in the molecular structure can enhance the pharmacological properties of the final drug products.
Used in Agrochemical Industry:
In the agrochemical sector, 3-(Aminomethyl)-5-bromopyridine 97% is employed as a precursor in the production of agrochemicals, specifically those with pesticidal or herbicidal properties, leveraging its reactivity and structural features to improve the effectiveness of these compounds.
Used in Research and Development:
3-(Aminomethyl)-5-bromopyridine 97% is utilized as a research chemical, providing scientists with a valuable tool for exploring new chemical reactions and syntheses. Its high purity ensures reliable results in experimental settings, facilitating the discovery of novel applications and compounds.
Used in Manufacturing Processes:
This chemical compound is also used in manufacturing processes within the chemical industry, where its unique structural attributes and reactivity are harnessed to produce a range of specialized organic compounds for various applications, including but not limited to, the creation of advanced materials and fine chemicals.

InChI:InChI=1/C6H7BrN2/c7-6-1-5(2-8)3-9-4-6/h1,3-4H,2,8H2

Upstream product

• 375854-08-3 3-bromo-5-(N,N-bis-tert-butoxycarbonyl)aminomethylpyridine 
• 136918-14-4 phthalimide 
• 37669-64-0 (5-bromopyridin-3-yl)methanol 
• 28733-43-9 5-bromonicotinamide 
• 856212-28-7 3-azidomethyl-5-bromo-pyridine 
• 219660-71-6 2-((5-bromopyridin-3-yl)methyl)isoindoline-1,3-dione 
• 35590-37-5 5-bromopyridine-3-carbonitrile 
• 113118-81-3 5-bromopyridine-3-carbaldehyde 
• 120277-69-2 5-bromo-pyridin-3-ylmethyl chloride 
• 29681-44-5 5-bromo-3-pyridine carboxylic acid methyl ester 
• 145743-86-8 methanesulfonic acid 5-bromo-pyridin-3-ylmethyl ester 
• 20826-04-4 5-bromo-3-pyridinecarboxylic acid 
• 908864-98-2 1-(5-bromopyridin-3-yl)-N,N-dimethylmethanamine 

Downstream Products

• 917373-58-1 N-[(5-Bromopyridin-3-yl)methyl]-10-[(2'-methoxy-1,1'-biphenyl-4-yl)carbonyl]-10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-3-carboxamide 
• 219660-72-7 1-(5-bromopyridin-3-yl)-N-(diphenylmethylene)methanamine 
• 943722-24-5 3-bromo-5-(tert-butoxycarbonyl)aminomethylpyridine 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR PARASITE CONTROL

The present invention relates in its broadest aspect to a compound of Formula I as provided herein, formulations comprising such a compound and corresponding uses thereof for the reduction of infestation with ectoparasites, in particular ectoparasites of the insect class, including fleas and mosquitoes and/or ectoparasites of the arachnid class, including ticks and mites, etc. Also provided herein are methods for preparing the formulations of the invention and methods for controlling ectoparasites using the compounds and/or formulations provided herein.

Discovery of 3-Pyridyl Isoindolin-1-one Derivatives as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors

Aldosterone synthase (CYP11B2) inhibitors have been explored in recent years as an alternative therapeutic option to mineralocorticoid receptor (MR) antagonists to reduce elevated aldosterone levels, which are associated with deleterious effects on various organ systems including the heart, vasculature, kidney, and central nervous system (CNS). A benzamide pyridine hit derived from a focused screen was successfully developed into a series of potent and selective 3-pyridyl isoindolin-1-ones CYP11B2 inhibitors. Our systematic structure-activity relationship study enabled us to identify unique structural features that result in high selectivity against the closely homologous cortisol synthase (CYP11B1). We evaluated advanced lead molecules, exemplified by compound 52, in an in vivo cynomolgus monkey acute adrenocorticotropic hormone (ACTH) challenge model and demonstrated a superior 100-fold in vivo selectivity against CYP11B1.

Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors

Cancer metabolism and epigenetics are among the most intensely pursued research areas in anticancer drug discovery. Here we report the first small molecules that simultaneously inhibit nicotinamide phosphoribosyltransferase (NAMPT) and histone deacetylase (HDAC), two important targets of cancer metabolism and epigenetics, respectively. Through iterative structure-based drug design, chemical synthesis, and biological assays, a highly potent dual NAMPT and HDAC inhibitor was successfully identified. Compound 35 possessed excellent and balanced activities against both NAMPT (IC50 = 31 nM) and HDAC1 (IC50 = 55 nM). It could effectively induce cell apoptosis and autophagy and ultimately led to cell death. Importantly, compound 35 showed excellent in vivo antitumor efficacy in the HCT116 xenograft model. This proof-of-concept study demonstrates the feasibility of discovering an inhibitor targeting cancer metabolism and epigenetics and provides an efficient strategy for multitarget antitumor drug discovery.

3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF

6-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 6-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-INDOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF

7-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 7-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.